{"id":28045,"date":"2024-05-17T15:23:49","date_gmt":"2024-05-17T09:53:49","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=28045"},"modified":"2024-06-19T12:05:35","modified_gmt":"2024-06-19T06:35:35","slug":"gsk-and-iteos-collaboration-for-belrestotug","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/gsk-and-iteos-collaboration-for-belrestotug","title":{"rendered":"GSK and iTeos Alliance Boosts Belrestotug Prospects in TIGIT Space"},"content":{"rendered":"\n

iTeos shares jump by 40%. GSK and iTeos collaboration for Belrestotug looks like a worthy wait. Hopes to ward off the negative sentiments around the volatile TIGIT space?<\/em><\/strong><\/p>\n\n\n\n

In the ever-evolving landscape of cancer immunotherapy<\/a>, the pursuit of effective treatment strategies continues to drive innovation and investment. Following the success of PD-(L) 1, TIGIT emerged as one of the most promising and prospective targets,<\/strong> garnering significant interest and investment from key players in the field. Interest in TIGIT has exploded over the past 3 years, with Merck<\/strong> and Roche<\/strong> quickly expanding their clinical development programs, while Bristol Myers<\/strong> and Gilead\/Arcus<\/strong> striking big deals to buy their way into the race.<\/p>\n\n\n\n

One of the most notable advancements in the anti-TIGIT landscape was the collaboration between GlaxoSmithKline <\/strong>and iTeos Therapeutics<\/strong>, around the time of peak TIGIT mania in 2021, culminating in a USD 625 million <\/strong>deal for the anti-TIGIT monoclonal antibody Belrestotug (EOS-448),<\/strong> paying more initially than Bristol Myers and Gilead combined. Back then, GSK\u2019s bet on belrestotug definitely represented a bold move as they believed in Belrestotug\u2019s unique attributes, including its distinct epitope binding and potential monotherapy activity, at the time when TIGIT space<\/a> was quite volatile. <\/p>\n\n\n\n

On the other side, development progress has also encountered hurdles. The setback of Roche\u2019s tiragolumab in the SKYSCRAPER trials in 2022 cast a pall over the TIGIT class,<\/strong> however, iTeos remains committed to advancing EOS-448 with GSK, despite investor caution amid the deflation of the TIGIT bubble, evidenced by the disparity between its cash reserves and market cap. Optimism surged in 2023<\/strong> with leaked interim positive findings from a Phase III trial of tiragolumab, leading to a market bump for anti-TIGIT drug developers. In addition, Roche continues to turn tables with the recently reported Phase III (SKYSCRAPER-08 study) TIGIT Win at the ASCO Gastro Cancer Meeting. However, it\u2019s premature to expect smooth sailing ahead for tiragolumab, and further data analysis is needed to fully assess its potential.<\/p>\n\n\n\n

Even though GSK\/iTeos remained tight-lipped around its anti-TIGIT for a long time, now we know that iTeos\u2019s advantage lies in its use of GSK\u2019s JEMPERLI as the PD-1 combo drug, which has shown comparable efficacy to Merck\u2019s KEYTRUDA in the PERLA study. This gives GSK\/iTeos an edge as KEYTRUDA serves as their trial\u2019s comparator, whereas Roche and Gilead\/Arcus lack direct KEYTRUDA comparisons for their anti-TIGIT MAbs.<\/p>\n\n\n\n

Expectations are high for iTeos Therapeutics with multiple clinical data readouts expected in 2024<\/strong>, including eagerly awaited full interim data from the Phase II Galaxies Lung-201 study. Moreover, recently disclosed positive findings from interim assessments surpassed predefined efficacy benchmarks by demonstrating clinically significant activity and notable tumor reduction, along with a safety profile consistent with the TIGIT: PD-1 class<\/a>, which have prompted a substantial 40% increase in iTeos shares<\/strong>. We continue to anticipate that any meaningful sign of clinical activity for belrestotug could place belrestotug very close to the lead in the TIGIT space.<\/p>\n\n\n\n

TIGIT Competitive Landscape<\/strong><\/p>\n\n\n\n

Potential key competitors in the TIGIT space<\/a> include Beigene\u2019s <\/strong>and Novartis\u2019s ociperlimab, Merck\u2019s vibostolimab, <\/strong>and Arcus Biosciences\u2019s domvanalimab<\/strong>.\u00a0\u00a0<\/p>\n\n\n\n

<\/span><\/p>\n

\n<\/colgroup>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n

Drug Name<\/span><\/p>\n<\/td>\n

\n

Company<\/span><\/p>\n<\/td>\n

\n

Phases<\/span><\/p>\n<\/td>\n

\n

Conditions<\/span><\/p>\n<\/td>\n

\n

NCT Number<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Domvanalimab<\/span><\/p>\n<\/td>\n

\n

Arcus Biosciences<\/span><\/p>\n<\/td>\n

\n

Phase II<\/span><\/p>\n<\/td>\n

\n

NSCLC<\/span><\/p>\n<\/td>\n

\n

NCT04262856<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

NCT04791839<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

NCT05676931<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Upper Gastrointestinal Tract Malignancies<\/span><\/p>\n<\/td>\n

\n

NCT05329766<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Phase III<\/span><\/p>\n<\/td>\n

\n

NSCLC<\/span><\/p>\n<\/td>\n

\n

NCT04736173<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

NCT05502237<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

NCT05211895<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Advanced Upper Gastrointestinal Tract Malignancies<\/span><\/p>\n<\/td>\n

\n

NCT05568095<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Ociperlimab<\/span><\/p>\n<\/td>\n

\n

BeiGene<\/span><\/p>\n<\/td>\n

\n

Phase II<\/span><\/p>\n<\/td>\n

\n

ESCC<\/span><\/p>\n<\/td>\n

\n

NCT04732494<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

NSCLC<\/span><\/p>\n<\/td>\n

\n

NCT05014815<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Phase III<\/span><\/p>\n<\/td>\n

\n

NSCLC<\/span><\/p>\n<\/td>\n

\n

NCT04746924<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Vibostolimab<\/span><\/p>\n<\/td>\n

\n

Merck<\/span><\/p>\n<\/td>\n

\n

Phase II<\/span><\/p>\n<\/td>\n

\n

Solid Tumors<\/span><\/p>\n<\/td>\n

\n

NCT05007106<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

NSCLC<\/span><\/p>\n<\/td>\n

\n

NCT04165070<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Colorectal Cancer<\/span><\/p>\n<\/td>\n

\n

NCT04895722<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Phase III<\/span><\/p>\n<\/td>\n

\n

Lung Cancer<\/span><\/p>\n<\/td>\n

\n

NCT04738487<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

NCT05298423<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

NCT05226598<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

SCLC<\/span><\/p>\n<\/td>\n

\n

NCT05224141<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Melanoma<\/span><\/p>\n<\/td>\n

\n

NCT05665595<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Tiragolumab<\/span><\/p>\n<\/td>\n

\n

Roche<\/span><\/p>\n<\/td>\n

\n

Phase II<\/span><\/p>\n<\/td>\n

\n

NSCLC<\/span><\/p>\n<\/td>\n

\n

NCT04832854<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Renal Cell Carcinoma<\/span><\/p>\n<\/td>\n

\n

NCT05805501<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Solid Tumors<\/span><\/p>\n<\/td>\n

\n

NCT05661578<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Phase II\/III<\/span><\/p>\n<\/td>\n

\n

Non-Squamous NSCLC<\/span><\/p>\n<\/td>\n

\n

NCT04619797<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Phase III<\/span><\/p>\n<\/td>\n

\n

NSCLC<\/span><\/p>\n<\/td>\n

\n

NCT04294810<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

NCT04513925<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

ESCC<\/span><\/p>\n<\/td>\n

\n

NCT04543617<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

EOS-448<\/span><\/p>\n<\/td>\n

\n

iTeos Therapeutics<\/span><\/p>\n<\/td>\n

\n

Phase II<\/span><\/p>\n<\/td>\n

\n

NSCLC<\/span><\/p>\n<\/td>\n

\n

NCT03739710<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

AZD2936<\/span><\/p>\n<\/td>\n

\n

AstraZeneca<\/span><\/p>\n<\/td>\n

\n

Phase II<\/span><\/p>\n<\/td>\n

\n

Gastric or GEJ Adenocarcinoma<\/span><\/p>\n<\/td>\n

\n

NCT05702229<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n\n\n\n

<\/div>\n\n\n\n

TIGIT inhibitors in the early phase (PhaseI &Phase I\/II) of development for solid tumors\u00a0<\/strong><\/p>\n\n\n\n

<\/span><\/p>\n

\n
\n<\/colgroup>\n\n\n\n\n\n\n\n\n\n\n
\n

Drug Name<\/span><\/p>\n<\/td>\n

\n

Company<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

HLX301<\/span><\/p>\n<\/td>\n

\n

Henlius Biotech<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

HLX53<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

JS006 or CHS-006<\/span><\/p>\n<\/td>\n

\n

Junshi Bioscience and Coherus Biosciences<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

SEA-TGT<\/span><\/p>\n<\/td>\n

\n

Seagen<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

COM-902<\/span><\/p>\n<\/td>\n

\n

Compugen<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

AB308<\/span><\/p>\n<\/td>\n

\n

Arcus Biosciences<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

PM1009<\/span><\/p>\n<\/td>\n

\n

Biotheus<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

AK130 <\/span><\/p>\n<\/td>\n

\n

Akeso<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/span><\/div>\n\n\n\n

<\/div>\n\n\n\n
\"TIGIT<\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"

iTeos shares jump by 40%. GSK and iTeos collaboration for Belrestotug looks like a worthy wait. Hopes to ward off the negative sentiments around the volatile TIGIT space? In the ever-evolving landscape of cancer immunotherapy, the pursuit of effective treatment strategies continues to drive innovation and investment. Following the success of PD-(L) 1, TIGIT emerged […]<\/p>\n","protected":false},"author":14,"featured_media":28048,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[22105,18911,903,18206,18935,18907,18909,18908],"industry":[17225],"therapeutic_areas":[17228],"class_list":["post-28045","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-belrestotug","tag-cancer-immunotherapy","tag-gsk","tag-iteos","tag-tigit","tag-tigit-inhibitors","tag-tigit-inhibitors-drugs","tag-tigit-inhibitors-therapies","industry-pharmaceutical","therapeutic_areas-oncology"],"acf":[],"yoast_head":"\nGSK-iTeos Collaboration Shines Amidst TIGIT Sector Uncertainty<\/title>\n<meta name=\"description\" content=\"Most notable advancements in anti-TIGIT landscape was collaboration between GlaxoSmithKline and iTeos Therapeutics for Belrestotug (EOS-448)\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/gsk-and-iteos-collaboration-for-belrestotug\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GSK-iTeos Collaboration Shines Amidst TIGIT Sector Uncertainty\" \/>\n<meta property=\"og:description\" content=\"Most notable advancements in anti-TIGIT landscape was collaboration between GlaxoSmithKline and iTeos Therapeutics for Belrestotug (EOS-448)\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/gsk-and-iteos-collaboration-for-belrestotug\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-05-17T09:53:49+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-06-19T06:35:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/17152035\/gsk-and-iteos-collaboration-for-belrestotug.png\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"GSK-iTeos Collaboration Shines Amidst TIGIT Sector Uncertainty","description":"Most notable advancements in anti-TIGIT landscape was collaboration between GlaxoSmithKline and iTeos Therapeutics for Belrestotug (EOS-448)","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/gsk-and-iteos-collaboration-for-belrestotug","og_locale":"en_US","og_type":"article","og_title":"GSK-iTeos Collaboration Shines Amidst TIGIT Sector Uncertainty","og_description":"Most notable advancements in anti-TIGIT landscape was collaboration between GlaxoSmithKline and iTeos Therapeutics for Belrestotug (EOS-448)","og_url":"https:\/\/www.delveinsight.com\/blog\/gsk-and-iteos-collaboration-for-belrestotug","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2024-05-17T09:53:49+00:00","article_modified_time":"2024-06-19T06:35:35+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/17152035\/gsk-and-iteos-collaboration-for-belrestotug.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/gsk-and-iteos-collaboration-for-belrestotug","url":"https:\/\/www.delveinsight.com\/blog\/gsk-and-iteos-collaboration-for-belrestotug","name":"GSK-iTeos Collaboration Shines Amidst TIGIT Sector Uncertainty","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/gsk-and-iteos-collaboration-for-belrestotug#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/gsk-and-iteos-collaboration-for-belrestotug#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/17152035\/gsk-and-iteos-collaboration-for-belrestotug.png","datePublished":"2024-05-17T09:53:49+00:00","dateModified":"2024-06-19T06:35:35+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Most notable advancements in anti-TIGIT landscape was collaboration between GlaxoSmithKline and iTeos Therapeutics for Belrestotug (EOS-448)","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/gsk-and-iteos-collaboration-for-belrestotug"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/gsk-and-iteos-collaboration-for-belrestotug#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/17152035\/gsk-and-iteos-collaboration-for-belrestotug.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/17152035\/gsk-and-iteos-collaboration-for-belrestotug.png","width":466,"height":284,"caption":"gsk-and-iteos-collaboration-for-belrestotug"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/05\/17152035\/gsk-and-iteos-collaboration-for-belrestotug-300x183.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Belrestotug<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Cancer immunotherapy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">GSK<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">iTeos<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">TIGIT<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">TIGIT Inhibitors<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">TIGIT Inhibitors Drugs<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">TIGIT Inhibitors Therapies<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Belrestotug<\/span>","<span class=\"advgb-post-tax-term\">Cancer immunotherapy<\/span>","<span class=\"advgb-post-tax-term\">GSK<\/span>","<span class=\"advgb-post-tax-term\">iTeos<\/span>","<span class=\"advgb-post-tax-term\">TIGIT<\/span>","<span class=\"advgb-post-tax-term\">TIGIT Inhibitors<\/span>","<span class=\"advgb-post-tax-term\">TIGIT Inhibitors Drugs<\/span>","<span class=\"advgb-post-tax-term\">TIGIT Inhibitors Therapies<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 2 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on May 17, 2024","modified":"Updated on Jun 19, 2024"},"absolute_dates_time":{"created":"Posted on May 17, 2024 3:23 pm","modified":"Updated on Jun 19, 2024 12:05 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/28045","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=28045"}],"version-history":[{"count":3,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/28045\/revisions"}],"predecessor-version":[{"id":28388,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/28045\/revisions\/28388"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/28048"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=28045"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=28045"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=28045"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=28045"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=28045"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}